If a dermatologist proposes tirbanibulin for diagnosed actinic keratoses while you are taking a GLP-1 medicine, ask for the application instructions and follow-up plan together. A short course still needs a later assessment of the treated skin.

Establish what is being treated

The American Academy of Dermatology recommends a skin examination for a suspected actinic keratosis, or AK, a precancerous growth. Treatment choice depends on findings including the number, location and appearance of lesions, previous skin cancer and other medical conditions. [3]

Ask the dermatologist to show you the diagnosed area and explain the proposed treatment's purpose. Bring the products you already use there and the names of your medicines. A rough patch should not be treated as an ordinary exfoliation problem without assessment.

What did the two trials measure?

Two randomized, double-blind trials enrolled 702 adults with four to eight AKs in a 25 cm² face or scalp area. Treatment lasted five days; complete clearance meant no clinically visible AK lesions in that area at day 57. [1]

TrialTirbanibulinVehicle
177/175 (44%)8/176 (5%)
297/178 (54%)22/173 (13%)

These are day-57 complete-clearance results. Both comparisons favored tirbanibulin (P<0.001). The trial population was predominantly older White men. [1]

The current U.S. KLISYRI label allows treatment fields up to 100 cm². It also describes a separate 105-person open-label safety study over that larger area. Keep that distinct from the original controlled efficacy trials. [2]

Why are two recurrence figures reported?

Among the 174 tirbanibulin recipients who achieved complete clearance, the paper reports one-year estimates of 47% for previously cleared lesions returning and 73% for any new or recurrent lesion in the treated area. The definitions differ. These are follow-up estimates among initial complete responders. [1]

The label uses the broader definition and reports 73% at 12 months after day 57. [2] Neither figure describes everyone who began treatment, and neither is an individual forecast.

If a treatment summary quotes “recurrence,” ask what counts: a lesion at its earlier location, a new lesion in the field, or either. Keep the definition and follow-up group beside the percentage. That makes the later examination's purpose easier to understand.

Plan for skin reactions and contact

The label warns that local skin reactions can be severe. Its patient instructions advise contacting the provider for worsening redness, scaling, crusting or swelling, or blisters, pus, ulcers or skin breakdown. Eye exposure requires flushing with water and prompt medical care. [2]

Ask how to contact the clinic and what to do if a reaction occurs outside office hours. Explain any difficulty following the instructions before starting. Request advice about the skincare products you use on that area rather than adding a remedy to manage the reaction yourself.

The label advises avoiding the eyes, mouth and lips, and waiting until skin has healed from previous treatment. [2] Have the dermatologist identify the boundaries of the treatment field. Do not use leftover medicine on another rough patch without assessment.

Keep the later skin review

AAD explains that people with multiple AKs can develop new lesions and skin cancer, and that their dermatologist sets the examination schedule. [3] Ask which changes should prompt an earlier appointment and how sun protection should fit around treatment.

Record the last application date, any reactions discussed with the clinic and the review appointment. Ask how the dermatologist will assess areas that remain rough or develop a new change. Finishing the packets should leave you with a clear next appointment rather than an assumption that every patch has cleared.

Athenex funded and oversaw the trials and paid for writing assistance. Authors disclosed consulting, employment and shareholding relationships. We reviewed the report's methods, results and declarations in the author-hosted PDF. [1] The trials do not establish a benefit specific to GLP-1 users.

For the earlier assessment question, see our rough sun-patch guide. Our persistent scaly-lip guide addresses a different location that needs its own diagnosis and instructions.

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Discuss medication, nutrition and cosmetic treatment decisions with qualified clinicians.

Sources

  1. Phase 3 trials of tirbanibulin ointment for actinic keratosisBlauvelt and colleagues; New England Journal of Medicine, 2021; author-hosted PDF↩ Back to text
  2. KLISYRI tirbanibulin 1% ointment: U.S. prescribing and patient informationDailyMed; updated June 24, 2026; prescribing text revised June 2024; checked October 29, 2026↩ Back to text
  3. Actinic keratosis: Diagnosis and treatmentAmerican Academy of Dermatology; updated February 23, 2022; checked October 29, 2026↩ Back to text